NAS:MDGL (USA) Also Trade In: Germany UK

Madrigal Pharmaceuticals Inc $ 119.11 7.17 (6.41%)

Volume:
71,459
Avg Vol (1m):
129,750
Market Cap $:
1.84 Bil
Enterprise Value $:
1.51 Bil
P/E (TTM):
0.00
P/B:
6.35
Warning! GuruFocus has detected 1 Severe warning sign with MDGL. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

Madrigal Pharmaceuticals Inc News and Headlines -

GuruFocus Articles Total 15
  • 1

The company needs to get liver disease drug approved and find help to commercialize it

The risk of investing in Viking Therapeutics Inc. (VKTX) may not be worth the potential rewards, according to a December article in Equities News. Investors who failed to heed this warning and bought shares of the San Diego-based biotechnology company haven’t been helped, but they haven’t been hurt either.

That’s because Viking is trading just about where it was in mid-December: $7.50. The company has made a nice recovery from mid-March, when it traded at a 52-week low of $3.26.

Viking’s future is closely tied to the success of one of only three drugs in its pipeline, VK2809. The company

149 Views    Barry Cohen    2020-06-15 20:19
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc. (ICPT).

The New York-based biotech could certainly use a boost. At just over $65, the stock is off about 50% from its 52-week high. TipRanks reported that the 13 analysts following Intercept rated it a strong buy with a target price of $151, but those estimates appear to be pre-coronavirus so investors should view them skeptically.

Intercept is hoping the

288 Views    Barry Cohen    2020-03-30 21:06
Inogen, Madrigal Pharmaceuticals have overweight recommendation ratings

The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks. Some investors are interested in these stocks because they believe the companies will rebound and reward them with impressive returns.

Investors are also aware that such a large decline can be a sign of financial distress, which will cause a major loss if it turns to insolvency.

The risk is very high with this kind of investment, but if investors look for companies that have no debt and a moderate to high current ratio, the risk can be significantly decreased.

205 Views    Alberto Abaterusso    2019-06-07 16:29
Details the CEO buys this past week for the following companies: Energy Transfer, American Assets Trust, Kellogg, ASGN and Madrigal Pharmaceuticals

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Energy Transfer CEO bought shares

Energy Transfer LP (ET) CEO Kelcy L. Warren bought 1 million shares on Nov. 19 at a price of $14.93. The price of the stock has decreased by 4.69% since.

Energy Transfer is a limited partnership company. Through its subsidiaries, the company owns and operates natural gas gathering systems, natural gas intrastate pipeline systems and gas processing plants. The company has a market cap of $37.24 billion. Its shares traded at $14.23 with a price-earnings ratio of 12.84 as of

37 Views    Joy Hu    2018-11-26 16:27
Twitter director makes largest sale of the week

The All-In-One Screener can be used to find insider buys and sales over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying/All Insider Selling to “$1,000,000+” and duration to "November 2015" and “December 2015.”

According to the above filters, the following are the recent buys from company insiders in the past week.

On Nov. 25, two insiders, both 10% owners, bought shares of WhiteHorse Finance Inc. (WHF). Sami Mnaymneh bought 3,269,446 shares in the company at the price of $13.55 per share and a total cost of

1109 Views    Tiziano Frateschi    2015-12-04 16:53

Following the stock picks of value investing gurus can be useful in investing research; however, that strategy alone can generate too many ideas to follow. For added conviction, GuruFocus provides a Double Buys page, where investors can sort what stocks both gurus and company insiders are purchasing.

By setting the Double Buys filters to only S&P 500 companies with recent trades of at least 20,000 shares, the following five companies are among those with the most guru and insider buys.

Kratos Defense & Security Solutions (KTOS)

Kratos is in the specialized security technology business and manufactures electronic components and systems

1631 Views    Sheila Dang    2015-06-18 15:49

The All-In-One Guru Screener can be used to find the most insider buys over the past week by clicking on the insiders tab and changing the settings for All Insider Buying to "1,000,000+ shares at $5,000,000" and Duration to "over the past 7 days."

Foundation Medicine Inc (FMI), Full Circle Capital Corp (FULL) and Syntha Pharmaceuticals Inc. (SNTA) were the 3 companies with the heaviest buys over the past week that met the criteria.

On April 7, CEO and President Gregg J Felton and Chairman,

1376 Views    Tiziano Frateschi    2015-04-10 20:43

According to GuruFocus list of 3-year lows, NeuStar Inc, Electro Rent Corp, Preformed Line Products Co, and Synta Pharmaceuticals Inc. have all reached their 3-year lows.

NeuStar Inc (NSR) Reached $24.61

The prices of NeuStar Inc (NSR) shares have declined to $24.61, which is 58.4% off the 3-year high of $57.29.

Neustar Inc has a market cap of $1.35 billion; its shares were traded at around $24.61 with a P/E ratio of 9.70 and P/S ratio of 1.58. Neustar Inc had an annual average earnings growth of 20.80% over the past 10 years. GuruFocus rated Neustar Inc

464 Views    Jimmy Xiao    2015-02-16 15:01

According to GuruFocus list of 5-year lows, these Guru stocks have reached their 5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp.

Vivus (NAS:VVUS) Reached $2.50

The prices of Vivus (VVUS) shares have declined to $2.50, which is only 3.6% above the 5-year low of $2.41. It is now 92.3% off the 5-year high of $31.21. Vivus is owned by 1 Gurus we are tracking. Among them, 1 have added to their positions during the past quarter. 1 reduced their positions. VIVUS was incorporated in 1991 as a California corporation and reincorporated in 1996 as a

951 Views    alicet236    2015-02-09 01:58

According to GuruFocus list of 5-year lows, these Guru stocks have reached their 5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Service Inc.

Synta Pharmaceuticals Inc (NAS:SNTA) Reached $2.69

The prices of Synta Pharmaceuticals Inc (SNTA) shares have declined to $2.69, which is only 5.6% above the 5-year low of $2.54. It is now 78.6% off the 5-year high of $11.88. Synta Pharmaceuticals Inc is owned by 2 Gurus we are tracking. Among them, 1 have added to their positions during the past quarter. 0 reduced their positions. Synta Pharmaceuticals Inc was incorporated

1162 Views    alicet236    2015-01-11 23:32

According to GuruFocus list of 5-year lows, these Guru stocks have reached their 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale Inc

Synta Pharmaceuticals Inc (NAS:SNTA) Reached $2.61

The prices of Synta Pharmaceuticals Inc (SNTA) shares have declined to $2.61, which is only 2.7% above the 5-year low of $2.54. It is now 78.6% off the 5-year high of $11.88. Synta Pharmaceuticals Inc is owned by 2 Gurus we are tracking. Among them, 1 have added to their positions during the past quarter. 0 reduced their positions. Synta Pharmaceuticals Inc was incorporated in Delware in

1065 Views    alicet236    2014-12-28 22:09
The following companies represent the most notable insider buys of the past week. In order to be considered for this list, the stock had to: · Be in at least one guru’s portfolio, · Have at least two insiders buying over 1,000 shares each. · Have at least one transaction cost over $100,000. [b]Achillion Pharmaceuticals ([url=http://www.gurufocus.com/stock/ACHN]ACHN[/url])[/b] In the past week, two directors made [url=http://www.gurufocus.com/insider/ACHN]significant buys[/url] into Achillion Pharmaceuticals. Director Jason Fisherman bought 10,000 shares at an average price of $7.87 per share. This transaction cost Fisherman a total of $78,700. Since his buy the price per share has increased approximately
1021 Views    Monica Wolfe    2013-06-10 22:08
According to [url=http://www.gurufocus.com/InsiderBuy.php]GuruFocus Insider Data[/url], these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: [b]Synta Pharmaceuticals Corp. (SNTA): President and CEO Safi R Bahcall Bought 10,000 Shares[/b] President and CEO of Synta Pharmaceuticals Corp. (SNTA) Safi R Bahcall bought 10,000 shares on 06/29/2012 at an average price of $6.53. SYNTA PHARMACEUTICALS CORP. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory
844 Views    GuruFocus    2012-07-08 01:43
The companies presented in this article, much like [url= http://vatalyst.com/2012/01/05/6-coiled-spring-biotech-stocks-to-consider-in-2012/]others in the biotech sector[/url], are likely to give high returns over the next three years based off of their technological advancements and large markets they intend to serve. Sophisticated investors should note that, while investing in biotech stocks can [url=http://vatalyst.com/2012/01/17/can-these-biotechs-make-you-money-in-2012/]produce great returns[/url], it is risky because FDA approvals of drugs offer a binary outcome either the company makes it or it does not. Mannkind ([url=http://www.gurufocus.com/stock/mnkd]MNKD[/url]) The stock has been on a downward trend since January 2011 after the [url=http://www.reuters.com/article/2011/01/19/mannkind-idUSN1925178720110119]FDA[/url] failed to approve its new inhaled insulin device (Afrezza), and requested
1519 Views    Vatalyst.com    2012-02-08 23:16
Magic Formula Investing (MFI), the strategy invented by hedge fund manager [url=http://www.gurufocus.com/StockBuy.php?GuruName=Joel+Greenblatt]Joel Greenblatt[/url] and covered by MagicDiligence, had a good year in 2010. There were several big winners, a rather limited number of large losers, and as a whole, the strategy delivered its adherents gains solidly beyond that returned by the S&P 500.Since the "bible" of MFI, [i][url=http://www.amazon.com/gp/product/0471733067?ie=UTF8&tag=magicdi05-20&linkCode=as2&camp=1789&creative=9325&creativeASIN=0471733067]The Little Book that Beats the Market[/url][/i], emphasizes including small caps to maximize the strategy's returns, below is a graph that shows the relative performance of MFI's "top 50 stocks over 50 million market cap" screen against the S&P 500 ETF (SPY). The
4680 Views    guruek    2011-01-02 03:29

Headlines Total 35
  • 1

2020-11-27 $ 119.11 (6.41%)
8:00am
2020-11-17 $ 120.22 (-0.59%)
2:27pm
2020-11-13 $ 128.09 (-0.09%)
7:00am
2020-11-05 $ 126.89 (-4.59%)
7:02am
2020-10-01 $ 118.19 (-0.45%)
11:00am
2020-09-03 $ 109 (-0.76%)
7:00am
2020-08-26 $ 105.36 (-0.72%)
7:00am
2020-08-06 $ 103.1 (-3.12%)
7:01am
2020-06-18 $ 110.97 (-0.08%)
8:07am
2020-06-06
12:29pm
2020-05-29 $ 116.42 (-2.98%)
8:38pm
2020-05-07 $ 88.23 (-0.08%)
7:01am
2020-04-14 $ 73.8 (10%)
7:00am
2020-02-26 $ 84.52 (-1.23%)
7:00am
2019-12-18 $ 90.62 (-3.59%)
7:00am
2019-12-11 $ 118.5 (1.1%)
7:00pm
2019-11-12 $ 103.57 (0.48%)
7:00pm
2019-11-06 $ 91.57 (-4.58%)
7:01am
2019-08-07 $ 88.68 (%)
7:05am
2019-07-11 $ 100.75 (-0.54%)
7:00am
2019-07-02 $ 103.17 (-3.15%)
7:01am
2019-06-07 $ 95.14 (4.4%)
11:29am
2019-06-04 $ 96.77 (3.23%)
7:00am
2019-05-16 $ 106.68 (3.18%)
7:01pm
2019-05-08 $ 104.09 (0.66%)
7:00am
2019-04-08 $ 133.57 (0.61%)
7:01am
2019-03-28 $ 126 (-1.98%)
7:00am
2019-02-27 $ 133.81 (-0.51%)
7:03am
2018-11-12 $ 186.51 (1.09%)
11:01am
2018-11-06 $ 208.38 (4.18%)
7:01am
2018-08-07 $ 245.51 (-0.67%)
7:03am
2018-06-07 $ 313.9 (4.28%)
11:00pm
2018-06-06 $ 301.03 (10.17%)
7:01pm
2018-05-31 $ 265.61 (144.96%)
7:03am
2018-05-08 $ 116.74 (-1%)
7:02am
Total 35
  • 1